Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.

MLA

Amat, S., et al. “Neoadjuvant Docetaxel for Operable Breast Cancer Induces a High Pathological Response and Breast-Conservation Rate.” British Journal of Cancer, vol. 88, no. 9, May 2003, pp. 1339–45. EBSCOhost, https://doi.org/10.1038/sj.bjc.6600916.

APA

Amat, S., Bougnoux, P., Penault-Llorca, F., Fétissof, F., Curé, H., Kwiatkowski, F., Achard, J.-L., Body, G., Dauplat, J., & Chollet, P. (2003). Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. British Journal of Cancer, 88(9), 1339–1345. https://doi.org/10.1038/sj.bjc.6600916

Chicago

Amat, S, P Bougnoux, F Penault-Llorca, F Fétissof, H Curé, F Kwiatkowski, J-L Achard, G Body, J Dauplat, and P Chollet. 2003. “Neoadjuvant Docetaxel for Operable Breast Cancer Induces a High Pathological Response and Breast-Conservation Rate.” British Journal of Cancer 88 (9): 1339–45. doi:10.1038/sj.bjc.6600916.